This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Illingworth, D. R. Articles by Bacon, S. Search for Related Content PubMed PubMed Citation Articles by Illingworth, D. R. Articles by Bacon, S.

Circulation, Vol 79, 590-596, Copyright © 1989 by American Heart Association

ARTICLES

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

DR Illingworth and S Bacon
Department of Medicine, Oregon Health Sciences University, Portland 97201.

We investigated the hypocholesterolemic effects of lovastatin alone and in combination with gemfibrozil on plasma lipids and lipoproteins in 12 adult patients with well-characterized heterozygous familial hypercholesterolemia. Plasma concentrations of low density lipoprotein (LDL) cholesterol decreased from 321 +/- 14 mg/dl on diet only to 207 +/- 8 mg/dl (-35.5%) on single-drug therapy with lovastatin at a dose of 40 mg twice daily, whereas triglyceride concentrations fell by 27.6% (from 145 +/- 20 to 105 +/- 20 mg/dl). Subsequent addition of gemfibrozil at a dose of 600 mg twice daily resulted in a nonsignificant further reduction in LDL cholesterol to 194 +/- 7 mg/dl (-39.6% change from baseline), whereas triglycerides decreased to 80 mg/dl (-44.8%, p less than 0.05 vs. single-drug therapy with lovastatin). Plasma concentrations of high density lipoprotein (HDL) increased slightly during lovastatin and combined drug therapy (from 45 +/- 4 mg/dl at baseline to 46 +/- 4 mg/dl on lovastatin to 48 +/- 4 mg/dl on lovastatin plus gemfibrozil). The response to combination drug therapy in individual patients was heterogeneous and clinically significant decreases in LDL cholesterol concentrations were noted in two of the 12 patients, whereas in three patients LDL cholesterol concentrations increased on the combined drug regimen. One patient developed an asymptomatic increase in creatine kinase on monotherapy with lovastatin and a more pronounced and symptomatic increase during combination drug therapy with lovastatin plus gemfibrozil.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C. Napoli, S. Lepore, P. Chiariello, M. Condorelli, and M. Chiariello Long-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined Hyperlipidemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 17 - 26. [Abstract] [PDF]

				Lovastatin Study Groups I Through IV Lovastatin 5-Year Safety and Efficacy Study Arch Intern Med, May 10, 1993; 153(9): 1079 - 1087. [Abstract] [PDF]

				L. R. Pierce, D. K. Wysowski, and T. P. Gross Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy JAMA, July 4, 1990; 264(1): 71 - 75. [Abstract] [PDF]